Press Releases

Month Year

Sep 21, 2018

New Data on Patient Acceptability and Genitourinary Effects of Evofem Biosciences' Amphora and its Role as a Multipurpose Vaginal pH Regulator (MVP-R) to be Presented at the 2018 American Society For Reproductive Medicine (ASRM) Annual Congress
Sep 18, 2018

Evofem Biosciences to Present at Upcoming Investor Conferences
Aug 29, 2018

Rise in Prevalence of STDs Reported by CDC Supports Continued Development of Novel Solutions, Like Evofem's Product in Development, Amphora®, for the Prevention of Chlamydia
Aug 23, 2018

Evofem Biosciences to Present at 20th Annual Global Investment Conference on September 6, 2018
Aug 7, 2018

Evofem Biosciences' Chief Medical Officer, Dr. Kelly Culwell, to Present at #BlogHer18 Creators Summit
Aug 2, 2018

Evofem Biosciences Reports Second Quarter 2018 Financial Results and Provides Corporate Update

Phase 3 Trial of Amphora for Hormone-free Contraception Continues to Move Ahead of Schedule; Top Line Data now expected in Late 2018
Jul 19, 2018

Evofem Biosciences to Report Second Quarter 2018 Results and Provide Corporate Update on August 2, 2018

-- Conference Call Scheduled for 11:00 a.m. EDT --
May 29, 2018

Evofem Biosciences to Present at Jefferies Global Healthcare Conference on June 7, 2018
May 24, 2018

Evofem Biosciences Announces Closing of Public Offering of Common Stock and Warrants
May 22, 2018

Evofem Biosciences Announces Pricing of Public Offering of Common Stock and Warrants
Apr 24, 2018

Evofem Biosciences Announces Proposed Public Offering of Common Stock
Feb 21, 2018

Evofem Biosciences Receives Fast Track Designation for Amphora for Prevention of Chlamydia
Feb 16, 2018

Evofem Biosciences to Present at RBC Global Healthcare Conference
Feb 15, 2018

Evofem Biosciences Completes Enrollment of Phase 3 Contraceptive Trial of Amphora Ahead of Schedule

Trial Data Expected First Quarter 2019
Jan 23, 2018

Evofem Biosciences Announces First Patient Enrolled in Phase 2b/3 STI Trial of Amphora® and Expects Phase 3 Contraceptive Clinical Trial Data First Quarter 2019

STI Trial Investigates Amphora for Prevention of Urogenital Chlamydia Trachomatis Infection in Women
Jan 17, 2018

Evofem Announces Closing Of Merger With Neothetics

Commences Trading on NASDAQ Capital Market on Thursday, January 18, 2018 Under Ticker Symbol "EVFM"
Nov 16, 2017

Form S-4 Filed with SEC
Oct 17, 2017

Neothetics, Inc. and Evofem Biosciences, Inc. Announce Merger Agreement to Create Women’s Health Company
Jul 27, 2017

Evofem Biosciences Announces First Patient Enrolled in a Phase 3 Clinical Trial of AMPHORA® (L-lactic Acid, citric acid, and potassium bitartrate) for Prevention of Pregnancy
Jun 29, 2017

AMPHORA® (L-lactic Acid, citric acid, and potassium bitartrate) Receives "Qualified Infectious Disease Product" (QIDP) Designation from the FDA
Dec 16, 2016

Evofem Biosciences Appoints Dr. David Friend as Chief Scientific Officer
Aug 29, 2016

Evofem Biosciences Appoints Russell Barrans as Chief Commercial Officer
Aug 17, 2016

Evofem Biosciences Announces First Patient Enrolled in a Clinical Trial to Determine the Effect and Duration of Amphora Gel on Vaginal pH
Aug 4, 2016

Evofem secures $25 million in Series D funding

EVOFEM SECURES $25.0 MILLION IN SERIES D FUNDING
Jun 15, 2016

Evofem to Address the Cavendish Global Health Impact Forum at Biocom on Innovations in Reproductive Health Care around the globe.

Show per page